Tryptophan Metabolism in Kidney Disease

This study has been completed.
Information provided by:
Charite University, Berlin, Germany Identifier:
First received: September 23, 2008
Last updated: July 13, 2009
Last verified: July 2009
Tryptophan metabolism in kidney disease will be investigated in patients with chronic kidney disease stages (ADOQI 3-5). Tryptophan levels and respective catabolites will be assessed under hemodialysis.

Chronic Kidney Disease

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Charite University, Berlin, Germany:

Primary Outcome Measures:
  • Course of plasma tryptophan level and levels of tryptophan metabolites under standard low-flux hemodialysis. [ Time Frame: does not apply ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: January 2007
Estimated Study Completion Date: October 2008
Patients with chronic kidney disease stage 3
patients with chronic kidney disease stage 4
patients with chronic kidney disease stage 5 (ESRD)
Controls (no kidney disease)


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
tertiary care academic center, university hospital

Inclusion Criteria:

  • Chronic kidney disease (for > 3months) stages (National Kidney foundation/ADOQI): 3-5

Exclusion Criteria:

  • Signs of infection or systemic inflammation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00758537

Charite University Medicine Berlin
Berlin, Germany, 13353
Sponsors and Collaborators
Charite University, Berlin, Germany
Principal Investigator: Petra Reinke, Md PhD Charite University Medicine
  More Information

No publications provided

Responsible Party: Prof. Dr. Petra Reinke MD, Charite UNiversity Medicine Berlin, Germany Identifier: NCT00758537     History of Changes
Other Study ID Numbers: TRY1STU 
Study First Received: September 23, 2008
Last Updated: July 13, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Charite University, Berlin, Germany:
Assessment of tryptophan and tryptophan catabolites and IDO-activity in patients with chronic kidney disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Urologic Diseases processed this record on February 04, 2016